The Incidence Mortality and Survival of Malignant Chondrosarcoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2022 Database Analysis
Author(s)
Filip Stanicic, PhD (c), Dimitrije Grbic, PhD (c), Vlad Zah, DPhil.
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
OBJECTIVES: Exploring the disease burden of chondrosarcoma in the US using the most recent Surveillance, Epidemiology, and End Results (SEER) database released in April 2025.
METHODS: Data from 17 US cancer registries (2000-2022) were retrieved and analyzed using SEER*Stat. The target population included malignant chondrosarcoma patients. Outcomes were crude incidence and mortality rates (per 100,000 population) and survival rates (percentages at 1-year and 5-year endpoints).
RESULTS: Most patients had unspecified chondrosarcoma subtype (73.5%), were 20-64 years old (64.9%), males (55.9%), non-Hispanic Whites (70.3%), married (56.8%), from metropolitan counties (89.1%), and with annual household income (AHI) of $65,000-$90,000 (47.8%). The chondrosarcoma incidence rate was 0.322. Subtypes with the highest incidence were unspecified (0.237), myxoid (0.043), and dedifferentiated (0.023). Among population subgroups, higher rates were reported for ≥65-year-olds (0.790), males (0.364), non-Hispanic Whites (0.417), and <$40,000 AHI (0.402). Trends showed an increasing incidence of dedifferentiated chondrosarcoma (2.5 annual percent change [APC], p<0.050) and a decreasing incidence of mesenchymal chondrosarcoma (-1.6 APC, p<0.050). The chondrosarcoma mortality rate was 0.119. The highest mortality among subtypes had unspecified (0.078), dedifferentiated (0.018), and myxoid (0.017). Across population subgroups, higher rates were observed for ≥65-year-olds (0.562), males (0.149), non-Hispanic Whites (0.164), and <$40,000 AHI (0.165). A significant trend was reported only for the unknown/unspecified chondrosarcoma subtype with increasing values over the years (5.2 APC, p<0.050). The highest 1-year survival was demonstrated for clear-cell (98.6%) and the lowest for dedifferentiated chondrosarcoma (53.2%). The highest 5-year survival was observed for juxtacortical (95.1%) and the lowest for dedifferentiated (23.7%).
CONCLUSIONS: The study findings showed an alarming chondrosarcoma burden, with the highest proportion of undetermined chondrosarcoma subtype. Dedifferentiated chondrosarcoma had one of the highest incidence rates among known subtypes, an increasing incidence trend, with the lowest 1-year and 5-year survival. The need for equal healthcare access and novel treatments is urgent.
METHODS: Data from 17 US cancer registries (2000-2022) were retrieved and analyzed using SEER*Stat. The target population included malignant chondrosarcoma patients. Outcomes were crude incidence and mortality rates (per 100,000 population) and survival rates (percentages at 1-year and 5-year endpoints).
RESULTS: Most patients had unspecified chondrosarcoma subtype (73.5%), were 20-64 years old (64.9%), males (55.9%), non-Hispanic Whites (70.3%), married (56.8%), from metropolitan counties (89.1%), and with annual household income (AHI) of $65,000-$90,000 (47.8%). The chondrosarcoma incidence rate was 0.322. Subtypes with the highest incidence were unspecified (0.237), myxoid (0.043), and dedifferentiated (0.023). Among population subgroups, higher rates were reported for ≥65-year-olds (0.790), males (0.364), non-Hispanic Whites (0.417), and <$40,000 AHI (0.402). Trends showed an increasing incidence of dedifferentiated chondrosarcoma (2.5 annual percent change [APC], p<0.050) and a decreasing incidence of mesenchymal chondrosarcoma (-1.6 APC, p<0.050). The chondrosarcoma mortality rate was 0.119. The highest mortality among subtypes had unspecified (0.078), dedifferentiated (0.018), and myxoid (0.017). Across population subgroups, higher rates were observed for ≥65-year-olds (0.562), males (0.149), non-Hispanic Whites (0.164), and <$40,000 AHI (0.165). A significant trend was reported only for the unknown/unspecified chondrosarcoma subtype with increasing values over the years (5.2 APC, p<0.050). The highest 1-year survival was demonstrated for clear-cell (98.6%) and the lowest for dedifferentiated chondrosarcoma (53.2%). The highest 5-year survival was observed for juxtacortical (95.1%) and the lowest for dedifferentiated (23.7%).
CONCLUSIONS: The study findings showed an alarming chondrosarcoma burden, with the highest proportion of undetermined chondrosarcoma subtype. Dedifferentiated chondrosarcoma had one of the highest incidence rates among known subtypes, an increasing incidence trend, with the lowest 1-year and 5-year survival. The need for equal healthcare access and novel treatments is urgent.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH245
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Oncology, Rare & Orphan Diseases